New drug KP-001 put to the heart safety test
NCT ID NCT06649942
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study checks whether a new drug called KP-001 affects the heart's electrical activity (QT interval) in 40 healthy adults. Participants receive single doses of KP-001, a placebo, or moxifloxacin (a control drug known to affect the QT interval) in random order. The goal is to see if KP-001 causes any heart rhythm changes, which is a key safety step before testing the drug for medical conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KP-001
What this could lead to
If this study shows KP-001 does not affect heart rhythm, it could support further development of the drug for its intended use.
What could go wrong
This is an early Phase 1 safety study in healthy volunteers, not designed to test effectiveness. The drug may still cause heart rhythm changes or other side effects in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS - MALE AND FEMALE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Parexel Early Phase Clinical Unit - Los Angeles
Glendale, California, 91206, United States